ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in several upcoming healthcare investor events in January, 2022.

Conference Presentation Details:

H.C. Wainwright BioConnect 2022 Conference

• Monday, January 10, 2022 at 12:00 pm ET (6:00 pm CET); on-demand on January 10-13, 2022
  

JP Morgan 40^th Annual Virtual Healthcare Conference

• Wednesday, January 12, 2022 at 7:30 am ET (1:30 pm CET)
  

Baader Helvea Swiss Equities Conference

• Wednesday, January 12, 2022 at 10:30 am ET (4:30 pm CET)
  

Conference Participation Details:

The Octavian Seminar 2022

• Friday, January 14, 2022
  

All webcasted presentations will be made available on the Molecular Partners website.

About Molecular Partners AG  

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs 

For further details, please contact:  Seth Lewis  seth.lewis@molecularpartners.com  Tel: +1 781 420 2361  Shai Biran, Ph.D.  shai.biran@molecularpartners.com  Tel: +1 978 254 6286  Thomas Schneckenburger, European IR & Media  thomas.schneckenburger@molecularpartners.com  Tel: +41 79 407 9952